NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

HIV Prevention With PrEP Among People on Opioid Replacement Therapy

RecruitingPhase 4

Sponsor: Cara Spence

Conditions: HIV - Human Immunodeficiency Virus

Interventions: Simultaneous administration of OAT and oral PrEP at existing pharmacy-based programs

Countries: Canada

The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest / acceptability of long-lasting injectable options for human immunodeficiency virus (HIV) prevention.

Eligibility overview

Sex: ALL

Age: 16 Years to —

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* HIV negative
* Ongoing behaviors with potential HIV exposure as assessed by a clinician
* Regularly engaged with their respective OAT program at least 3 days a week for the past 2 weeks
* Report willingness to return for follow-up visits

Exclusion Criteria:

* Creatine clearance \<30 mL/min or any medical condition or medication known to be contraindicated with the use of Emtricitabine/Tenofovir Alafenamide (F/TAF) or Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
* Taken PrEP within the last 24 hours at the time of screening or enrollment
* Deemed appropriate by a clinician for HIV Post-Exposure Prophylaxis at the time of screening or enrollment

Locations (6)

Calgary, Alberta, Canada
Regina, Saskatchewan, Canada
Saskatoon, Saskatchewan, Canada
Saskatoon, Saskatchewan, Canada
Saskatoon, Saskatchewan, Canada
Saskatoon, Saskatchewan, Canada